HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Helene Curtis

This article was originally published in The Rose Sheet

Executive Summary

Helene Curtis: Lowers earnings prediction for FY 1996 (ending Feb. 29) and reports an expected loss for the third quarter (ending Nov. 30), the firm announces Nov. 20. Helene Curtis expects pre-tax earnings for the year in the $20-$24 mil. range while the firm's tax rate "will be somewhat higher" than last year. The firm previously predicted earnings would "approximate" FY 1995 when the firm reported $36.2 mil. in pre-tax profit ("The Rose Sheet" Oct. 2, p. 10). President and CEO Ronald Gidwitz said the firm's FY 1996 results have been affected by "continued weakness in our Japanese business and by lower-than-expected sales" in North America for the third quarter to date. As a result, Helene Curtis will be spending more on advertising "to support [its] brands where appropriate," Gidwitz said...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel